FDA Class II Recall: Golden State Medical Supply's Niacin Extended-Release Tablets Fail Dissolution
Golden State Medical Supply Inc. has initiated a Class II recall for 24,869 bottles of NIACIN Extended-Release Tablets, 1,000 mg, due to failed dissolution specifications. This nationwide recall impacts patient treatment for dyslipidemia, necessitating immediate supply chain review and alternative sourcing strategies for procurement directors and regulatory affairs heads to mitigate disruption.
FDA-Mandated Recall: Golden State Medical Supply's Niacin Extended-Release Fails Dissolution
Golden State Medical Supply Inc., based in Camarillo, CA, has initiated a Class II voluntary recall for 24,869 bottles of NIACIN Extended-Release Tablets, USP, 1,000 mg. The critical reason cited for this action, identified under recall number D-0158-2026, is a failure to meet dissolution specifications. This directly impacts the drug's ability to release its active ingredient, Niacin, at the intended rate, which is crucial for therapeutic efficacy and patient safety, particularly in managing dyslipidemia. For procurement directors, this means an immediate assessment of existing inventory of affected product (NDC: 51407-268-90) is paramount to prevent distribution of sub-potent medication. Regulatory affairs heads must understand that dissolution failures can lead to unpredictable drug absorption, potentially causing either sub-therapeutic effects or, conversely, a rapid release that exacerbates side effects like flushing, thereby compromising patient treatment outcomes. The recall, initiated on October 20, 2025, affects multiple lots with expiry dates ranging from October 2025 to May 2026, underscoring a systemic quality control issue that demands urgent attention from both the packager and the manufacturer.
Operational Impact: Golden State Medical Supply's Role in Niacin Supply Chain
The recall highlights a complex supply chain structure for NIACIN Extended-Release Tablets, USP, 1,000 mg. While Golden State Medical Supply Inc. of Camarillo, CA 93012-8601 is the recalling firm and packager, the product was manufactured by Kremers Urban Pharmaceuticals, Inc., a subsidiary of Lannett Company, Inc., located in Seymour, IN 47274. This dual-entity involvement means that supply chain VPs must conduct a thorough investigation to pinpoint the exact stage where the dissolution failure occurred—whether it originated in the manufacturing process at Kremers Urban or during packaging and quality control at Golden State Medical Supply. Understanding this distinction is critical for root cause analysis and implementing effective corrective and preventive actions (CAPA). The nationwide distribution pattern in the USA for these 24,869 bottles suggests a significant market presence, meaning a broad impact on pharmacies, distributors, and ultimately, patients. Business development executives should note that such quality issues can erode brand trust and create market opportunities for competitors with robust quality assurance protocols for Niacin products.
Supply Chain Vulnerability: Niacin Extended-Release Market Disruption
The Class II recall of NIACIN Extended-Release Tablets, USP, 1,000 mg, distributed nationwide, creates an immediate supply chain vulnerability for healthcare providers and patients relying on this specific formulation. With 24,869 bottles impacted, procurement directors face the challenge of securing alternative supplies to prevent treatment interruptions for patients managing dyslipidemia. The failure in dissolution specifications implies that the drug may not deliver its intended therapeutic effect consistently, posing a risk to patient health outcomes. This situation necessitates rapid action to quarantine affected stock (NDC: 51407-268-90, lot numbers including GS044385, GS044979, GS045797, GS046415, GS047197, GS047786, GS048477, GS049480, GS048873, GS049733, GS050224, GS050721, GS050722, GS051145, GS051726, GS052484, GS053612, GS054987, GS054409, GS055697, GS056192, GS056886, GS058077, GS057330) and initiate return processes. Business development executives should assess the competitive landscape for Niacin Extended-Release products, as this recall could shift market share towards alternative manufacturers and suppliers who can demonstrate consistent product quality and supply reliability.
Mitigating Risk: Identifying Alternative Niacin Suppliers
Given the recall of NIACIN Extended-Release Tablets, USP, 1,000 mg, procurement teams must immediately activate their contingency plans for sourcing this critical molecule. While the ChemLifeIntel Knowledge Graph does not specify alternative suppliers for this particular product, the generic nature of Niacin (Vitamin B3) suggests that multiple manufacturers exist globally. Procurement directors should prioritize identifying and qualifying new or existing alternative suppliers with proven track records of regulatory compliance and robust quality control, particularly concerning dissolution testing. Key considerations include geographic diversity to mitigate future regional supply shocks, comprehensive audit trails, and the ability to meet stringent qualification timelines, which can often extend from 6 to 18 months for pharmaceutical products. Regulatory affairs heads should ensure that any new supplier's documentation and manufacturing processes meet FDA standards to avoid future compliance issues. Proactive multi-sourcing strategies are essential to build resilience against such quality-related recalls and ensure uninterrupted supply of essential medicines like Niacin.
Regulatory Environment and Compliance Imperatives
While the ChemLifeIntel Knowledge Graph does not provide specific prior regulatory actions for Golden State Medical Supply Inc. or Kremers Urban Pharmaceuticals, Inc., this recall occurs within a heightened global regulatory environment. Recent parallel events, such as Essential Wellness Pharma's Class II recall of Progesterone Injection due to sterility assurance failures in June 2026, and Amgen's Tavneos facing an FDA hearing over independent data review, underscore the FDA's intensified scrutiny on pharmaceutical quality and safety. This context signals to regulatory affairs heads that all aspects of Good Manufacturing Practices (GMP) and Good Distribution Practices (GDP) are under close examination. A dissolution failure, even for a Class II recall, can trigger more extensive FDA inspections focusing on quality systems, analytical methods, and change control procedures. Companies must ensure their Quality Management Systems (QMS) are not merely compliant but demonstrably effective in preventing critical quality attribute failures. Proactive investment in quality assurance and robust supplier qualification programs is no longer just a best practice but a commercial imperative to maintain market access and avoid costly recalls and reputational damage.
Remediation and Future Outlook for Niacin Supply
The ongoing Class II recall initiated by Golden State Medical Supply Inc. requires a comprehensive remediation strategy. As a voluntary, firm-initiated recall, the company is responsible for investigating the root cause of the failed dissolution specifications, implementing robust corrective and preventive actions (CAPA), and ensuring effective communication with affected customers. The FDA will closely monitor the recall's effectiveness, including the firm's outreach to distributors and pharmacies, and the disposition of returned products. Supply chain VPs should anticipate potential FDA follow-up inspections at both Golden State Medical Supply's packaging facility in Camarillo, CA, and Kremers Urban Pharmaceuticals' manufacturing site in Seymour, IN, which will likely focus on quality control, analytical testing, and manufacturing process validation for Niacin Extended-Release. The long-term outlook for Niacin supply from these specific entities will depend on the thoroughness and effectiveness of their remediation efforts. Failure to adequately address the underlying quality issues could lead to further regulatory actions, including potential Warning Letters or even import alerts if international distribution were involved, impacting global market access and necessitating long-term strategic adjustments for procurement and business development executives.